A288330 Stock Overview
A clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bridge Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,075.00 |
| 52 Week High | ₩6,100.00 |
| 52 Week Low | ₩1,464.17 |
| Beta | 0.91 |
| 11 Month Change | -46.89% |
| 3 Month Change | 1.99% |
| 1 Year Change | 17.33% |
| 33 Year Change | -69.25% |
| 5 Year Change | n/a |
| Change since IPO | -79.61% |
Recent News & Updates
Shareholder Returns
| A288330 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.8% | -4.5% | 2.4% |
| 1Y | 17.3% | 21.1% | -4.0% |
Return vs Industry: A288330 underperformed the KR Biotechs industry which returned 22.4% over the past year.
Return vs Market: A288330 exceeded the KR Market which returned -3.8% over the past year.
Price Volatility
| A288330 volatility | |
|---|---|
| A288330 Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A288330's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A288330's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 35 | James Jungkue Lee | bridgebiorx.com |
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade.
Bridge Biotherapeutics, Inc. Fundamentals Summary
| A288330 fundamental statistics | |
|---|---|
| Market cap | ₩155.01b |
| Earnings (TTM) | -₩33.11b |
| Revenue (TTM) | n/a |
9,999x
P/S Ratio-4.7x
P/E RatioIs A288330 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A288330 income statement (TTM) | |
|---|---|
| Revenue | -₩340.00 |
| Cost of Revenue | ₩83.23m |
| Gross Profit | -₩83.23m |
| Other Expenses | ₩33.03b |
| Earnings | -₩33.11b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -656.84 |
| Gross Margin | 24,479,005.88% |
| Net Profit Margin | 9,738,783,985.29% |
| Debt/Equity Ratio | 0% |
How did A288330 perform over the long term?
See historical performance and comparison